Anavex Life Sciences (AVXL) Enterprise Value (2010 - 2025)
Anavex Life Sciences (AVXL) reported Enterprise Value of -$131.7 million for Q4 2025, down 9.09% on a YoY basis from -$144.9 million in Q4 2024, and down 28.44% sequentially from -$102.6 million in Q3 2025.
Anavex Life Sciences (AVXL) Enterprise Value (2010 - 2025) Analysis & Trends
Anavex Life Sciences (AVXL) has 16 years of Enterprise Value data on file, last reported at -$131.7 million in Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 9.09% year-over-year to -$131.7 million; the trailing twelve-month figure through Dec 2025 stood at -$131.7 million (down 9.09% YoY), and the FY2025 full-year result was -$102.6 million, up 22.4% from the prior year.
- Enterprise Value eased to -$131.7 million in Q4 2025, from -$102.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$75.9 million in Q1 2021 to a low of -$157.6 million in Q2 2021.
- A 5-year average of -$136.1 million and a median of -$143.7 million in 2022 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value tumbled 470.47% in 2021 and gained 27.09% in 2025, its largest moves.
- Tracing AVXL's Enterprise Value over 5 years: stood at -$151.1 million in 2021, then advanced by 4.98% to -$143.6 million in 2022, then slipped by 0.1% to -$143.8 million in 2023, then gained by 15.99% to -$120.8 million in 2024, then decreased by 9.09% to -$131.7 million in 2025.
- Business Quant data shows AVXL's Enterprise Value at -$131.7 million in Q4 2025, -$102.6 million in Q3 2025, and -$101.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Anavex Life Sciences | 229.83 Mn | 98.08 Mn | - | -131.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -131.75 Mn |
| Sep 30, 2025 | -102.58 Mn |
| Jun 30, 2025 | -101.16 Mn |
| Mar 31, 2025 | -115.77 Mn |
| Dec 31, 2024 | -120.78 Mn |
| Sep 30, 2024 | -132.19 Mn |
| Jun 30, 2024 | -138.76 Mn |
| Mar 31, 2024 | -139.39 Mn |
| Dec 31, 2023 | -143.77 Mn |
| Sep 30, 2023 | -151.02 Mn |
| Jun 30, 2023 | -154.82 Mn |
| Mar 31, 2023 | -153.47 Mn |
| Dec 31, 2022 | -143.62 Mn |
| Sep 30, 2022 | -149.16 Mn |
| Jun 30, 2022 | -153.20 Mn |
| Mar 31, 2022 | -153.34 Mn |
| Dec 31, 2021 | -151.15 Mn |
| Sep 30, 2021 | -152.11 Mn |
| Jun 30, 2021 | -157.56 Mn |
| Mar 31, 2021 | -75.86 Mn |